A new analysis of diabetes medications Avandia (rosiglitazone) and Actos (pioglitazone) revealed that the risk of heart attack and/or heart failure, or death were the same, approximately 4%. The study has been published in the latest issue of Circulation: Cardiovascular Quality and Outcomes , an American Heart Association journal.
Takeda Pharmacuetical Co. makes Actos, while GlaxoSmithKline (GSK) makes Avandia. (more…)
TUESDAY, Aug. 24 (HealthDay News) — A new study finds that the risk of heart attacks or death after taking the glucose-lowering diabetes drugs Avandia and Actos are about the same.
This is a direct contradiction to numerous other studies that found that the risk was elevated for Avandia (rosiglitazone) but not for Actos (pioglitazone). The findings are, however, in line with some other previous studies, further muddying (more…)
Most people with diabetes who have weight–loss bariatric surgery may be able to stop taking their diabetes medications‚ lowering healthcare costs, according to a study by researchers at Johns Hopkins in Baltimore.
Study authors looked at 2‚235 adults with type 2 diabetes who underwent stomach–reducing surgery. Six months after surgery‚ nearly 75 percent of patients had eliminated their diabetes medications‚ and 84.5 percent of (more…)
A new study has found that popular diabetes drugs rosiglitazone (Avandia) and pioglitazone (Actos) increase the risk of fracture in older women.
Researchers, writing in the Journal of Clinical Endocrinology & Metabolism, looked at a large study known as TRIAD to identify 786 cases of fractures and compare them to 2,657 patients who had diabetes but no fracture history. Out of the overall group, 54 patients were women under age 50, 457 (more…)